Promimic (PRO) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 reached 8.8 MSEK, up 1% year-over-year, with total operating income at 11.0 MSEK, a 16% increase compared to Q1 2024.

• Operating result improved slightly to -3.7 MSEK from -3.8 MSEK, while net result after tax declined to -4.5 MSEK from -3.5 MSEK year-over-year.

• Several new strategic agreements were signed, including a major partnership with Lincotek and an expanded collaboration with Curiteva.

• Promimic's HAnano Surface technology demonstrated a 45% reduction in bacterial presence on implant surfaces, supporting infection prevention claims.

• Cash flow improved to -0.9 MSEK from -3.7 MSEK, with cash and cash equivalents at 34.1 MSEK at period end.

Financial highlights

• Net sales: 8.8 MSEK (8.7 MSEK Q1 2024); operating income: 11.0 MSEK (9.4 MSEK Q1 2024).

• Operating result: -3.7 MSEK (-3.8 MSEK Q1 2024); net result after tax: -4.5 MSEK (-3.5 MSEK Q1 2024).

• Royalty and license income (rolling four quarters): 19.5 MSEK, up 17% year-over-year.

• EBITDA: -2.4 MSEK (-2.5 MSEK Q1 2024); equity ratio: 82% (84% Q1 2024).

• Cash flow from operations: 1.0 MSEK (-0.6 MSEK Q1 2024); cash at period end: 34.1 MSEK (46.6 MSEK Q1 2024).

Outlook and guidance

• Focus remains on commercial expansion in the US orthopedic implant market and strengthening production capacity to meet demand.

• Financial target: reach 100 MSEK in sales and EBITDA margin above 40% by 2026.

• Strategic partnerships and new license agreements are expected to drive future growth.